scholarly journals Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

2019 ◽  
Vol 8 (10) ◽  
pp. 4678-4687 ◽  
Author(s):  
Tommy A. Brown ◽  
Kevin Byrd ◽  
Timothy J. Vreeland ◽  
Guy T. Clifton ◽  
Doreen O. Jackson ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Binding Protein ◽  
Peptide Vaccine ◽  
Final Analysis ◽  
Folate Binding Protein

scholarly journals Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

Oncotarget ◽  
2016 ◽  
Vol 8 (9) ◽  
pp. 15912-15923 ◽  
Author(s):  
Doreen O. Jackson ◽  
Kevin Byrd ◽  
Timothy J. Vreeland ◽  
Diane F. Hale ◽  
Garth S. Herbert ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Interim Analysis ◽  
Binding Protein ◽  
Protein Vaccine ◽  
Folate Binding Protein ◽  
Gm Csf

Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e14031-e14031 ◽  
Author(s):  
Julia M. Greene ◽  
Erika J Schneble ◽  
John S. Berry ◽  
Alfred F. Trappey ◽  
Timothy J. Vreeland ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Phase I ◽  
Cancer Patients ◽  
Binding Protein ◽  
Dose Finding ◽  
Protein Vaccine ◽  
Folate Binding Protein ◽  
Preliminary Results ◽  
Gm Csf

EP-1351: PHASE I/II trial of 3DCRT+MDR Brachy given concurrently to Caelyx and CDDP to high risk endometrial cancer patients

2014 ◽  
Vol 111 ◽  
pp. S105
Author(s):  
C. Varveris ◽  
A. Varveris ◽  
M. Mazonaki ◽  
J. Stratakis ◽  
A. Spanakis ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
High Risk ◽  
Phase I ◽  
Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document